NovoLog (insulin aspart) / Novo Nordisk 
Welcome,         Profile    Billing    Logout  

17 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
NovoLog (insulin aspart) / Novo Nordisk
2016-002910-38: Basal and pre-meal insulin versus standard therapy for the inpatient manegement of type 2 diabetes: The IDA2 study Basal og bolus insulin versus standard behandling til indlagte patienter med type 2 diabetes: IDA2 studiet

Ongoing
4
100
Europe
Insulin degludec, insulin aspart, Suspension for injection in pre-filled pen, Solution for injection in pre-filled pen, Tresiba, Novorapid
Hvidovre University Hospital, Novo Nordisk A/S
Type 2 diabetes Type 2 diabetes, Type 2 diabetes Type 2 diabetes, Diseases [C] - Hormonal diseases [C19]
 
 
2013-004737-33: A prospective, multicenter, randomized, open-label study of 12 week duration to evaluate the effect of VILDagliptin added to insulin on glycaemic control in haemoDIALyzed patients with type 2 diabetes: probe analysis of CGM Etude prospective randomisée multicentrique d’évaluation de la VILDagliptine associée à l’insuline sur le contrôle glycémique chez les patients hémoDIALysés diabétiques de type 2 : étude VILDDIAL

Not yet recruiting
4
70
Europe
Vildagliptine, Tablet, Solution for injection, Suspension for injection, Galvus, LANTUS 100 unités/ml solution injectable, LANTUS 100 unités/ml solution injectable en cartouche, LANTUS 100 unités/ml solution injectable en cartouche pour OptiClik, Lantus OptiSet 100 unités/ml solution injectable en stylo prérempli, Lantus SoloStar 100 unités/ml solution injectable en stylo prérempli, Levemir 100 U/ml, solution injectable en cartouche, Levemir 100 U/ml, solution injectable en stylo prérempli, Levemir InnoLet 100 U/ml, solution injectable en stylo prérempli, Levemir FlexTouch 100 U/ml, solution injectable en stylo prérempli, Apidra 100 unités/ml solution injectable en flacon, Apidra 100 unités/ml solution injectable en cartouche, Apidra 100 unités/ml solution injectable en cartouche pour OptiClik, Apidra 100 unités/ml solution injectable en stylo prérempli, Apidra SoloStar 100 unités/ml solution injectable en stylo prérempli, Humalog 100 UI/ml, solution injectable en flacon, Humalog 100 UI/ml, solution injectable en cartouche, Humalog Mix25 100 UI/ml suspension injectable en flacon, Humalog Mix25 100 UI/ml suspension injectable en cartouche, Humalog Mix50 100 UI/ml suspension injectable en flacon, Humalog Mix50 100 UI/ml suspension injectable en cartouche, Humalog BASAL 100 UI/ml suspension injectable en cartouche, Humalog Pen 100 UI/ml, solution injectable, Humalog Mix25 100 UI/ml Pen, suspension injectable, Humalog Mix50 100 UI/ml Pen, suspension injectable, Humalog BASAL 100 UI/ml Pen, suspension injectable, Humalog 100 UI/ml KwikPen, solution injectable, Humalog Mix25 100 UI/ml KwikPen, suspension injectable, Humalog Mix50 100 UI/ml KwikPen, suspension injectable, Humalog BASAL 100 UI/ml KwikPen, suspension injectable, NovoRapid 100 U/ml, solution injectable, NovoRapid Penfill 100 U/ml, solution injectable en cartouche, NovoRapid FlexPen 100 U/ml, solution injectable en stylo prérempli, NovoRapid InnoLet 100 U/ml, solution injectable en stylo prérempli, NovoRapid FlexTouch 100 U/ml, solution injectable en stylo prérempli
Hôpitaux Universitaires de Strasbourg, HÔPITAUX UNIVERSITAIRES DE STRASBOURG, NOVARTIS PHARMASAS
haemodialyzed patients with type 2 diabetes patients hémodialysés et présentant un diabète de type 2, haemodialyzed patients with type 2 diabetes patients hémodialysés et présentant un diabète de type 2, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
2015-003666-85: Investigation of Appropriate Timing of Additional Insulin Dosing for Fat and Protein in Children with Type 1 Diabetes using Multiple Daily Injections

Not yet recruiting
4
40
Europe
Insulin Aspart (NovoRapid), Solution for injection, Novorapid
Oxford University Hospitals NHS Trust, National Institute of Health Research funding from OUHT, NovoNordisk Research Foundation
Type 1 diabetes, Insulin-dependent diabetes, Diseases [C] - Hormonal diseases [C19]
 
 
2019-001281-14: A study that investigates the effects of fast-acting insulin (FIASP®) on blood sugars in comparison to a different fast-acting insulin (NovoRapid®) around exercise in participants with type 1 diabetes Der Einfluss von schnell-wirkendem Insulin (FIASP®) auf den Blutzuckerspiegel im Vergleich zu einem anderen schnell wirkendem Insulin (NovoRapid®) vor, während und nach sportlicher Belastung

Ongoing
4
44
Europe
Fiasp, Novorapid, Tresiba, A10AB05, Injection, Fast-acting insulin aspart (Fiasp® 100 U/mL) in 3 mL FlexTouch®, Insulin aspart (NovoRapid® 100 U/mL) in 3 mL FlexPen®, Insulin degludec (Tresiba® 100 U/mL) in 3 mL FlexTouch®
Medical University of Graz, Novo Nordisk
Type 1 Diabetes Typ 1 Diabetes Mellitus, Participants in this study have type 1 diabetes which is defined as the lack of own insulin production. Probanden in dieser Studie haben Typ 1 Diabetes Mellitus welches sich durch das Ausbleiben einer körpereigenen Insulinproduktion auszeichnet., Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
TRANSITION-T2D, NCT04538352: Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With Type-2 Diabetes Mellitus

Completed
4
60
US
Semaglutide, Ozempic, Insulin Degludec, Tresiba, Insulin aspart, Novolog
The Cleveland Clinic, Novo Nordisk A/S
Type 2 Diabetes
03/23
11/23
2020-001158-23: Fast-Acting Insulin Aspart and Insulin Pump Settings:“THE FAST PUMP SETTING STUDY”

Not yet recruiting
4
40
Europe
Fiasp, Novorapid, Solution for injection/infusion, Fiasp, NovoRapid
Steno Diabetes Center Copenhagen, Steno Diabetes Center Copenhagen, Novo Nordisk A/S
Type 1 diabetes, Participants in this study have type 1 diabetes which is defined as lack of own insulin production Type 1 diabetes er en kronisk sygdom som er karakteriseret ved at man ikke kan producere insulin til at få blodglukose ned., Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
2018-004680-31: A comparison of the faster-acting insulin Fiasp® versus insulin Novorapid® in the treatment of women with type 1 or type 2 diabetes during pregnancy and lactation

Not yet recruiting
3
220
Europe
Solution for injection in pre-filled pen, Solution for injection/infusion, Fiasp, Novorapid
Lene Ringholm, Novo Nordisk
Type 1 and type 2 diabetes during pregnancy and lactation, Insulin requiring diabetes during pregnancy and lactation, Diseases [C] - Hormonal diseases [C19]
 
 
2020-005309-18: A research study to see how well the new weekly medicine IcoSema, which is a combination of insulin icodec and semaglutide, controls blood sugar level in people with type 2 diabetes compared to insulin glargine taken daily with insulin aspart (COMBINE 3) Klinikai vizsgálat annak tanulmányozására, hogy az IcoSema, az ikodek inzulin és a szemaglutid kombinációjából álló, hetente alkalmazott új gyógyszer mennyire kontrollálja jól a 2-es típusú cukorbetegek vércukorszintjét a naponta, aszpart inzulinnal együtt alkalmazott glargin inzulinnal összehasonlítva (COMBINE 3)

Ongoing
3
680
Europe
IcoSema 700 U/mL + 2 mg/mL PDS290, Solution for injection in pre-filled pen, Solution for injection, Lantus SoloStar, NovoRapid FlexPen
Novo Nordisk A/S, Novo Nordisk A/S
Diabetes Mellitus, Type 2 2-es típusú diabétesz mellitus, Type 2 diabetes, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
NCT04460326: Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus

Completed
3
137
US
Insulin glargine, Lantus®, NovoLog, NovoLog®, Insulin Fiasp, Fiasp®, Standard carbohydrate diet
Boston Medical Center, Novo Nordisk A/S
Type 2 Diabetes Treated With Insulin
05/23
05/23
INHALE-1, NCT04974528: Afrezza® Study in Pediatrics

Active, not recruiting
3
319
US
Afrezza, Technosphere Insulin, Rapid-acting Insulin Analog, insulin aspart, insulin lispro, insulin glulisine, Novolog®, Fiasp®, Humalog®, Admelog®, Apidra®, Basal Insulin, insulin glargine, insulin degludec, insulin detemir, Lantus®, Abasaglar®, Basaglar®, Semglee®, Toujeo®, Tresiba®, Levemir®
Mannkind Corporation, Jaeb Center for Health Research
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
09/24
04/25
NCT05539872: Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers

Completed
2/3
69
US
I004, Insulin Aspart, a rapid-acting human insulin analogue, NovoLog
Amphastar Pharmaceuticals, Inc.
Pharmacokinetics, Pharmacodynamics
01/23
01/23
2011-002780-16: A study of efficacy and safety of the glucose lowering drug Exenatide on patients with suspected acute stroke and hyperglycemia

Ongoing
2
100
Europe
Byetta, Novorapid, A10AB05, Solution for injection in pre-filled pen, Byetta, Novorapid
Karolinska Institutet, Karolinska institutet Södersjukhuset
Patients with hyperglycemia and symptoms of acute stroke will be randomized to either subcutaneous injection with 10ug of Byetta or standard care., Patients with hyperglycemia and symptoms of acute stroke will be randomized to either subcutaneous injection with 10ug of the glucose lowering drug Byetta or standard care against hyperglycemia., Diseases [C] - Cardiovascular Diseases [C14]
 
 
NCT05737576: The Pharmacokinetics and Pharmacodynamics Between HR011408 and NovoRapid® in Healthy Subject

Completed
1
61
RoW
HR011408 injection; NovoRapid®, NovoRapid®；HR011408 injection
Jiangsu HengRui Medicine Co., Ltd.
Diabetes
10/23
12/23
NCT05719961: Bioequivalence Study of INS062 and Pharmacokinetics and Pharmacokinetics Study of Single Injection of HR20014 in Healthy Subjects

Recruiting
1
60
RoW
INS062 injection, Insulin Aspart, HR20014 injection, Insulin Aspart 30 Injection
Jiangsu HengRui Medicine Co., Ltd.
Diabetes
07/23
07/23
NCT05754424: AT278, NovoRapid® and Humulin® R (U500) in Glucose Clamp Study

Completed
1
41
Europe
AT278, NovoRapid, Humulin R 500 UNT/ML Injectable Solution
Arecor Limited
Diabetes Mellitus, Type 2
01/24
02/24
NCT06375031: Comparison of HR011408 and NovoRapid® in Subjects With Diabetics

Recruiting
1
30
RoW
HR011408 injection; HR011408 injection Placebo, NovoRapid®; HR011408 injection Placebo, HR011408 injection Placebo; HR011408 injection
Jiangsu HengRui Medicine Co., Ltd.
Diabetes
07/24
07/24
NCT02879409: HbA1c Variability in Type II Diabetes

Active, not recruiting
N/A
150
RoW
Metformin, Glucophage, Gliclazide, Diamicron, Diamicron MR, Sitagliptin, Januvia, Liraglutide, Victoza, Pioglitazone, Actos, Dapagliflozin, Forxiga, Farxiga, human insulin, novorapid, glargine
Weill Cornell Medical College in Qatar, Hamad Medical Corporation, Sidra Medical and Research Center, University of Hull
Diabetes Mellitus Type 2
10/23
10/24

Download Options